Cleared Special

Bioland G-425-2V Blood Glucose Monitoring System, Bioland G-425-2 Blood Glucose Monitoring System (K202739) - FDA 510(k) Clearance

Class II Chemistry device cleared through the Special 510(k) pathway - typically does not require clinical trials.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2022
Decision
693d
Days
Class 2
Risk

K202739 is an FDA 510(k) clearance for the Bioland G-425-2V Blood Glucose Monitoring System, Bioland G-425-2 Blood Gluco.... Classified as System, Test, Blood Glucose, Over The Counter (product code NBW), Class II - Special Controls.

Submitted by Bioland Technology, Ltd. (Shenzhen, CN). The FDA issued a Cleared decision on August 12, 2022 after a review of 693 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1345 - the FDA in vitro diagnostics and chemistry framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Chemistry submissions.

View all Bioland Technology, Ltd. devices

Submission Details

510(k) Number K202739 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 18, 2020
Decision Date August 12, 2022
Days to Decision 693 days
Submission Type Special
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
605d slower than avg
Panel avg: 88d · This submission: 693d
Pathway characteristics
Modification to existing cleared device.

Device Classification

Product Code NBW System, Test, Blood Glucose, Over The Counter
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1345
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - NBW System, Test, Blood Glucose, Over The Counter

All 165
Devices cleared under the same product code (NBW) and FDA review panel - the closest regulatory comparables to K202739.
SuperCheck Pro Blood Glucose Monitoring System
K213061 · Ok Biotech Co., Ltd. · Oct 2022
GlucoLeader Enhance 2 Blood Glucose Monitoring System
K212248 · Hmd Biomedical, Inc. · Aug 2022
GlucoSure Link Blood Glucose Monitoring System
K212140 · Apex BioTechnology Corp. · Aug 2022
FORA ADVANCED GD40 Glucose, ß-Ketone and Cholesterol Monitoring System
K201037 · Taidoc Technology Corporation · Jun 2022
IWL2020 Blood Glucose Monitoring System
K203711 · Roche Diabetes Care, Inc. · May 2022
MTM301 Blood Glucose and Ketone Monitoring System
K202534 · Apex BioTechnology Corp. · Apr 2022